Tag: Medical Devices

Top Priorities for Life Science GBS Organizations in 2023: Scaling R&D Capabilities | Virtual Roundtable

Virtual Roundtable

Top Priorities for Life Science GBS Organizations in 2023: Scaling R&D Capabilities

April 05, 2023 |
9:30 am EDT | 7 PM IST

Life Sciences GBS organizations today have evolved into strategic partners for their enterprises, driving both operational and technological advancements. As part of the evolution, Life Sciences GBS organizations are increasingly supporting critical functions, including R&D operations, and scaling up these capabilities has been a top priority.

Join this virtual roundtable as our experts and your peers discuss and explore the vision, effort, and support required for scaling R&D capabilities from offshore/nearshore delivery centers.

What you will take away:

In this collaborative session, we’ll uncover the key aspects of building R&D capabilities in GBS, such as:

  • The vision for housing R&D capabilities in GBS and the value proposition of having an offshore/nearshore presence
  • Key enablers and challenges in offshoring/nearshoring core capabilities
  • Success driving actions from Life Sciences GBS leaders
  • Success stories from best-in-class peers

Who should attend?

  • GBS leaders
  • GBS Strategy leaders
  • GBS site leaders
  • GBS R&D/Clinical leaders

Virtual Roundtable Guidelines

The only price of admission is participation. Attendees should be prepared to share their experiences and be willing to engage in discourse.

Participation is limited to enterprise leaders (no service providers). Everest Group will approve each attendance request to ensure an appropriate group size and mix of participants. The sessions are 90 minutes in duration and include introductions, a short presentation, and a facilitated discussion.

Connected Medical Device Services PEAK Matrix® Assessment 2022

Top Connected Medical Device Services

With the increased adoption of remote monitoring technologies, wearables, and smart implants, the medical devices industry is shifting toward building a connected care ecosystem that seamlessly integrates people, technology, and data across the care continuum. Enterprises are looking to augment their current device portfolios with digital technologies to support the patient journey across care settings. To support enterprises on their connected care journeys, providers are ramping up both their engineering and digital capabilities through industry-specific partnerships, IP, and innovation centers to benefit stakeholders across the healthcare and MedTech ecosystems.

DOWNLOAD THE FULL REPORT Connected Medical Device Services PEAK Matrix® Assessment 2022

Connected Medical Device Services PEAK Matrix® Assessment 2022: What is the Scope?

  • Industry: life sciences
  • Geography: global
  • The assessment is based on Everest Group’s annual RFI process for 2022, interactions with leading connected medical device service providers, client reference checks, and an ongoing analysis of the connected medical device services market

What is in this PEAK Matrix® Report:

In this research, we present an assessment of 19 medical device service providers featured on the Connected Medical Device Services PEAK Matrix®. This report examines:

  • Connected medical device services market trends

  • The service provider landscape for connected medical device services

  • Service providers on several capability- and market success-related dimensions

LEARN MORE ABOUT Connected Medical Device Services PEAK Matrix® Assessment 2022

Our Thinking

Applications of the Metaverse in Healthcare Services
Market Insights™

Applications of the Metaverse in Healthcare Services

Leveraging the Metaverse to Address Healthcare Industry Challenges
Market Insights™

Leveraging the Metaverse to Address Healthcare Industry Challenges

GettyImages 1332002332

IMC 2022 Highlights: India Mobile Conference Focuses on 5G Business Opportunities

Abstract colorful big data machine learning algorithm visualization.

Unleashing the Potential of Data in Insurance – The Road Ahead

Pharma and MedTech Services Buyers Provider Selection Criteria
Market Insights™

Pharma and MedTech Services Buyers’ Provider Selection Criteria

Life Sciences Services Buyer Satisfaction
Market Insights™

Life Sciences Services Buyer Satisfaction

Life Sciences Services Buyers Provider Selection Criteria by Buyer Size
Market Insights™

Life Sciences Services Buyers’ Provider Selection Criteria, by Buyer Size

Key Cybersecurity Service Growth Opportunities in the Healthcare and Life Sciences Industry
Market Insights™

Key Cybersecurity Service Growth Opportunities in the Healthcare and Life Sciences Industry

Life Sciences Regulatory and Medical Affairs Operations
PEAK Matrix®

Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024

04 25 2024 Key Insights 1200x628

Key Insights: The Evolving Commercial Technology Landscape in Life Sciences

Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
PEAK Matrix®

Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

MedTech Operations
PEAK Matrix®

MedTech Operations PEAK Matrix® Assessment 2023

What is the PEAK Matrix®?

The PEAK Matrix® provides an objective, data-driven assessment of service and technology providers based on their overall capability and market impact across different global services markets, classifying them into three categories: Leaders, Major Contenders, and Aspirants.

LEARN MORE ABOUT Top Service Providers

Is the Medical Device Industry Prepared for the New EU Medical Device and In Vitro Diagnostic Regulations? | Blog

The EU had planned to implement a new set of regulations – the European Union Medical Device Regulations (EU MDR) in May 2021 and In Vitro Diagnostic Regulations (IVDR) in May 2022 – to establish stringent device controls, improve transparency and product traceability, and strengthen clinical evaluation and post-market surveillance. But a series of overwhelming events has forced EU regulators to shift the MDR implementation from May 2020 to May 2021.

The global COVID-19 pandemic is the primary cause of this deferment. However, constant pushbacks from trade associations have also played a role, as has strong evidence of the industry’s under-preparedness to comply. For example:

  • Under the existing Medical Device Directive (MDD) there are 58 Notified Bodies (NBs) –organizations that have been designated by a member state to assess the conformity of certain products before being placed on the EU market – that cater to the industry. With the new regulations, there will be only 11 NBs with an EU MDR designation and three with an IVDR designation to handle a workload of 500,000 medical device technologies available in the European market
  • Reclassification and up-classification of both existing and new products under the new regulations put considerable financial and administrative strain on small and mid-sized firms
  • Increased complexity in documenting the additional requirements of clinical evaluation and post-marketing surveillance, as the industry moves toward a lifecycle approach, to necessitate proactive monitoring of device performance.

To overcome these challenges, stakeholders across the medical device industry, including medical device manufacturers, contract research organizations (CROs), and service providers, should focus on specific areas.

  • Medical device manufacturers should outline a compliance strategy to adapt to the regulatory reforms. As the regulations also increase the cost and time required to enter the European market, they should also build alternative business plans, with a focus on budgeting resources and redefining product portfolio and market entry strategies to remain competitive. To achieve compliance and build a collaborative and transparent framework, they should also update their legacy systems and embrace cloud-based solutions
  • CROs and service providers can provide strategic support to medical device manufacturers in building a regulatory roadmap and enhancing technological capabilities. Also, the new regulations’ stringent data requirements will increase the focus on data collection and management tools, and data governance and security. Service providers should align their clinical and post-market offerings with EU MDR and IVDR offerings to gain traction. For instance, HCL’s regulatory Center of Excellence (CoE) now provides end-to-end MDR and IVDR compliance services to manufacturers.

The medical device industry is exploring multiple ways to continue to stay relevant in the European market. While some organizations are leveraging the EU MDR and IVDR transitional provisions (MDD and IVDR certificates issued before May 2017, which will remain valid until they expire or May 2024, whichever comes earlier) to extend their market presence, others are building their regulatory capabilities and deploying both internal and external workforces to do so. Cook Medical, for instance, is hiring 20 full-time EU MDR-specific roles and working with over 70 contract-based individuals. Likewise, service providers such as Capgemini and TCS are seeking to hire regulatory specialists.

The launch date’s extension by a year might just provide the much-needed relief and time all stakeholders need to build their capabilities to comply with the new regulations.

For more insights on the impact of EU MDR and IVDR on the medical device industry, please see our recently published viewpoint Regulatory Overhaul of the EU Medical Device Market or contact [email protected], [email protected], or [email protected].


How can we engage?

Please let us know how we can help you on your journey.

Contact Us

"*" indicates required fields

Please review our Privacy Notice and check the box below to consent to the use of Personal Data that you provide.